OBJECTIVE: To validate a useful version of the Motor Function Measure (MFM) in children with neuromuscular diseases aged <7 years old. DESIGN: Two prospective cohort studies that documented the MFM completion of children aged between 2 and 7 years old. SETTING: French-speaking rehabilitation departments from France, Belgium, and Switzerland. PARTICIPANTS: Healthy children (n=194) and children with a neuromuscular disease (n=88). INTERVENTIONS: Patients were rated by the MFM either once or twice by trained medical professionals, with a delay between the 2 MFMs ranging between 8 and 30 days. MAIN OUTCOME MEASURE: Intra- and interrater reliability of the MFM. RESULTS: The subtests making up the MFM-32, a scale monitoring severity and progression of motor function in patients with a neuromuscular disease in 3 functional domains, were carried out in healthy children aged 2 to 7 years. Twenty items of the MFM-32 were successfully completed by these children and were used to constitute the MFM-20. Principal component analysis of the MFM-20 confirmed the 3 functional domains. Inter- and intrarater reliability of the 3 subscores and total score were high (intraclass correlation coefficient >.90), and discriminant validity was good. CONCLUSIONS: The MFM-20 can be used as an outcome measure for assessment of motor function in young children with neuromuscular disease.
OBJECTIVE: To validate a useful version of the Motor Function Measure (MFM) in children with neuromuscular diseases aged <7 years old. DESIGN: Two prospective cohort studies that documented the MFM completion of children aged between 2 and 7 years old. SETTING: French-speaking rehabilitation departments from France, Belgium, and Switzerland. PARTICIPANTS: Healthy children (n=194) and children with a neuromuscular disease (n=88). INTERVENTIONS:Patients were rated by the MFM either once or twice by trained medical professionals, with a delay between the 2 MFMs ranging between 8 and 30 days. MAIN OUTCOME MEASURE: Intra- and interrater reliability of the MFM. RESULTS: The subtests making up the MFM-32, a scale monitoring severity and progression of motor function in patients with a neuromuscular disease in 3 functional domains, were carried out in healthy children aged 2 to 7 years. Twenty items of the MFM-32 were successfully completed by these children and were used to constitute the MFM-20. Principal component analysis of the MFM-20 confirmed the 3 functional domains. Inter- and intrarater reliability of the 3 subscores and total score were high (intraclass correlation coefficient >.90), and discriminant validity was good. CONCLUSIONS: The MFM-20 can be used as an outcome measure for assessment of motor function in young children with neuromuscular disease.
Authors: Lilian A Y Fernandes; Fátima A Caromano; Silvana M B Assis; Michele E Hukuda; Mariana C Voos; Eduardo V Carvalho Journal: Braz J Phys Ther Date: 2014 Nov-Dec Impact factor: 3.377
Authors: Rianne J M Goselink; Tim H A Schreuder; Karlien Mul; Nicol C Voermans; Maaike Pelsma; Imelda J M de Groot; Nens van Alfen; Bas Franck; Thomas Theelen; Richard J Lemmers; Jean K Mah; Silvère M van der Maarel; Baziel G van Engelen; Corrie E Erasmus Journal: BMC Neurol Date: 2016-08-17 Impact factor: 2.474
Authors: Rianne J M Goselink; Tim H A Schreuder; Nens van Alfen; Imelda J M de Groot; Merel Jansen; Richard J L F Lemmers; Patrick J van der Vliet; Nienke van der Stoep; Thomas Theelen; Nicol C Voermans; Silvère M van der Maarel; Baziel G M van Engelen; Corrie E Erasmus Journal: Ann Neurol Date: 2018-10-16 Impact factor: 10.422